|
1 |
2 |
3 |
| 1 |
dornase alfa |
cystic fibrosis |
Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis |
| 2 |
fialuridine |
pancreatitis |
In patients with chronic hepatitis B, treatment with fialuridine induced a severe toxic reaction characterized by hepatic failure, lactic acidosis, pancreatitis, neuropathy, and myopathy |
| 3 |
mediator |
pancreatitis |
Tumor necrosis factor-alpha (TNF alpha) is postulated to be a mediator of the systemic complications associated with acute pancreatitis |
| 4 |
pancreolauryl-test |
pancreatitis |
Non-invasive, technically uncomplicated and reliable pancreolauryl-test seems to be useful for screen estimation of pancreatic exocrine function impairment in patients after the acute pancreatitis |
| 5 |
rhDNase |
cystic fibrosis |
rhDNase in cystic fibrosis |
| 6 |
recombinant human DNase |
cystic fibrosis |
BACKGROUND--A phase II multicentre double blind placebo controlled study in 1993 showed that short term treatment (10 days) with recombinant human DNase I (rhDNase) was safe and improved pulmonary function in patients with cystic fibrosis with stable stage lung disease |
| 7 |
rhDNase |
cystic fibrosis |
CONCLUSIONS--Administration of rhDNase was safe, well tolerated, and improved pulmonary function in patients with cystic fibrosis |
| 8 |
dornase alpha |
cystic fibrosis |
A new approach to the respiratory problems of cystic fibrosis is dornase alpha, a mucolytic enzyme given by inhalation |
| 9 |
a 10 |
cystic fibrosis |
The purpose of this investigation was to measure the effects of a 10- to 14-day comprehensive, intensive hospital treatment program on peak exercise capacity, endurance capacity, respiratory function, weight change, and maximum inspiratory and expiratory mouth pressures in patients with cystic fibrosis with a pulmonary exacerbation |
| 10 |
Mad |
pancreatic cancer |
The transactivating activity resides in the conserved carboxy-terminal domain of Smad1 and is disrupted by a nonsense mutation that corresponds to null mutations found in Mad and in the related gene DPC4, a candidate tumour-suppressor gene in human pancreatic cancer |
| 11 |
TTP |
pancreatitis |
Similarly, in six of seven other cases from the medical literature the TTP/HUS occurred within 2-3 days of the onset of pancreatitis |
| 12 |
CPT-11 |
pancreatic cancer |
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study |
| 13 |
CPT-11 |
pancreatic cancer |
BACKGROUND: CPT-11 (irinotecan) is a semi-synthetic derivative of camptothecin and exerts its activity by inhibiting DNA topoisomerase I. A phase II study of this drug was performed in patients with pancreatic cancer |
| 14 |
CPT-11 |
pancreatic cancer |
CONCLUSION: CPT-11 is an interesting moderately effective drug in pancreatic cancer |
| 15 |
Dornase alfa |
cystic fibrosis |
Dornase alfa for cystic fibrosis |
| 16 |
Dornase alfa |
cystic fibrosis |
Dornase alfa for cystic fibrosis |
| 17 |
release |
pancreatitis |
We suggest that these factors precipitate acute pancreatitis by causing either excessive release of acinar [Ca2+]i, or damage to the integrity of mechanisms that restore low resting levels of [Ca2+]i, and that the consequent calcium toxicity is the key trigger in the pathogenesis of acute pancreatitis |
| 18 |
release |
pancreatitis |
We suggest that these factors precipitate acute pancreatitis by causing either excessive release of acinar [Ca2+]i, or damage to the integrity of mechanisms that restore low resting levels of [Ca2+]i, and that the consequent calcium toxicity is the key trigger in the pathogenesis of acute pancreatitis |
| 19 |
recombinant human DNase |
cystic fibrosis |
DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase |
| 20 |
rhDNase |
cystic fibrosis |
BACKGROUND--The clinical benefit of the administration of aerosolised recombinant human DNase (rhDNase) on pulmonary function in patients with cystic fibrosis has already been demonstrated but the biochemical action of rhDNase on DNA in bronchial secretions in vivo has not yet been investigated |
| 21 |
rhDNase |
cystic fibrosis |
METHODS--Sputum was collected from 135 patients with cystic fibrosis before and during treatment with aerosolised rhDNase and examined to ascertain DNA concentration and length by colorimetric assay and densitometry of gel separated DNA |
| 22 |
probe |
pancreatitis |
Using a new chemiluminescence probe (2-methyl-6-[p-methoxyphenyl]-3,7-dihydro-imidazol[1,2-1]pyrazin- 3-one; MCLA; a Cypridina luciferin analogue) and a highly sensitive photon counting system, O2- from the pancreatic surface of rats with experimental acute pancreatitis induced by 180 micrograms cerulein/kg was detected |
| 23 |
MCLA |
pancreatitis |
Using a new chemiluminescence probe (2-methyl-6-[p-methoxyphenyl]-3,7-dihydro-imidazol[1,2-1]pyrazin- 3-one; MCLA; a Cypridina luciferin analogue) and a highly sensitive photon counting system, O2- from the pancreatic surface of rats with experimental acute pancreatitis induced by 180 micrograms cerulein/kg was detected |
| 24 |
FUT-175 |
pancreatitis |
Rats with pancreatitis induced by retrograde injected Urografin, lipopolysaccharide, taurocholic acid plus enterokinase were treated with either intravenous (i.v.) FUT-175 (Nafamstat Mesilate), FUT-175 administered by retrograde pancreatic injection, i.v. terbutaline, i.v. piperacillin sodium, piperacillin sodium by retrograde pancreatic duct injection, or a combination of FUT-175 plus terbutaline and piperacillin |
| 25 |
pancreatitis-associated protein |
pancreatitis |
Changes in gene expression of pancreatitis-associated protein and pancreatic secretory trypsin inhibitors in experimental pancreatitis produced by pancreatic duct occlusion in rats: comparison with gene expression of cholecystokinin and secretin |
| 26 |
recombinant human DNase |
cystic fibrosis |
Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis |
| 27 |
bentiromide |
cystic fibrosis |
METHODS: Forty (40) normal volunteers, 18 adults with cystic fibrosis and four adults with celiac sprue, ingested a liquid test meal along with bentiromide, [13C6]PABA, and xylose (PABAX test) |
| 28 |
advantage |
pancreatitis |
In this study, we use a bile-infusion model of pancreatitis in the rat to show amelioration of disease severity as well as a distinct survival advantage by TNF alpha blockade using anti-TNF alpha polyclonal antibody |
| 29 |
DP |
pancreatic cancer |
The most frequent indication for PD was pancreatic cancer (36%) followed by chronic pancreatitis (26%); for DP it was chronic pancreatitis (28%) and cystic neoplasms (27%); and for TP, chronic pancreatitis (55%) |
| 30 |
DP |
pancreatitis |
The most frequent indication for PD was pancreatic cancer (36%) followed by chronic pancreatitis (26%); for DP it was chronic pancreatitis (28%) and cystic neoplasms (27%); and for TP, chronic pancreatitis (55%) |
| 31 |
DP |
pancreatitis |
The most frequent indication for PD was pancreatic cancer (36%) followed by chronic pancreatitis (26%); for DP it was chronic pancreatitis (28%) and cystic neoplasms (27%); and for TP, chronic pancreatitis (55%) |
| 32 |
keratinocyte growth factor |
pancreatic cancer |
Increased expression of keratinocyte growth factor in human pancreatic cancer |
| 33 |
1-hydroxyphenazine |
cystic fibrosis |
Scavenging of neutrophil-derived superoxide anion by 1-hydroxyphenazine, a phenazine derivative associated with chronic Pseudomonas aeruginosa infection: relevance to cystic fibrosis |
| 34 |
Lexipafant |
pancreatitis |
Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis |
| 35 |
Lexipafant |
pancreatitis |
The aims of the study were to determine whether the platelet-activating factor antagonist Lexipafant could alter the clinical course and suppress the inflammatory response of human acute pancreatitis |
| 36 |
Lexipafant |
pancreatitis |
During this time seven of 12 patients with severe acute pancreatitis who had Lexipafant recovered from an organ failure; only two of 11 with severe acute pancreatitis who had placebo recovered from an organ failure and two others developed new organ failure |
| 37 |
Lexipafant |
pancreatitis |
During this time seven of 12 patients with severe acute pancreatitis who had Lexipafant recovered from an organ failure; only two of 11 with severe acute pancreatitis who had placebo recovered from an organ failure and two others developed new organ failure |
| 38 |
Lexipafant |
pancreatitis |
This study provides a rationale for further clinical trials with the potent PAF antagonist Lexipafant in human acute pancreatitis |
| 39 |
rhDNase |
cystic fibrosis |
In 15 patients with cystic fibrosis, rhDNase was able in vitro to improve mucus transport capacities by simulated cough |
| 40 |
rhDNase |
cystic fibrosis |
[Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement] |
